Development of therapeutic vaccines by direct modification of cell membranes from surgically removed human tumor tissue with immunostimulatory molecules
Authors:
- Shanmugam NagarajanSNShanmugam Nagarajan
- Gary W BumgarnerGBGary W Bumgarner
- Periasamy SelvarajPSPeriasamy Selvaraj
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.Journal of Experimental Medicine, 1995
- Protein transfer of preformed MHC-peptide complexes sensitizes target cells to T cell cytolysisImmunity, 1994
- Uncovering of Functional Alternative CTLA-4 Counter-Receptor in B7-Deficient MiceScience, 1993
- Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma CellsScience, 1993
- Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4Cell, 1992
- Phenotypic expression of histocompatibility antigens in human primary tumours and metastasesClinical & Experimental Metastasis, 1989
- Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlates and evidence for a phosphatidylinositol membrane anchor.Journal of Experimental Medicine, 1987
- Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.Journal of Experimental Medicine, 1984
- A simple and rapid method for the preparation of plasma membranesBiochimica et Biophysica Acta (BBA) - Biomembranes, 1983
- Expression of DR Antigens in Freshly Frozen Human TumorsHybridoma, 1982